IMPORTANT DRUG WARNING

Subject: Risk Evaluation and Mitigation Strategy (REMS) for SUBOXONE®
(buprenorphine and naloxone) Sublingual Film CIII, SUBOXONE®
(buprenorphine and naloxone) Sublingual Tablets CIII, and SUBUTEX®
(buprenorphine) Sublingual Tablets CIII for opioid dependence due to
risks of accidental overdose, misuse, and abuse.

<Date>

Dear Pharmacist:

The purpose of this letter is to inform you of a Risk Evaluation and Mitigation
Strategy (REMS) for SUBOXONE sublingual film, SUBOXONE sublingual tablets,
SUBUTEX sublingual tablets, and the generic equivalent products, hereafter
collectively called buprenorphine-containing products. This REMS does not apply
to buprenorphine-containing products that are dispensed to patients in an Opioid
Treatment Program (OTP) under 42 CFR Part 8 because the care of OTP patients is
subject to specific requirements under those regulations.

The FDA has determined that a REMS is necessary to ensure that the benefits
of buprenorphine-containing products for opioid dependence outweigh the
potential risks of accidental overdose, misuse, and abuse. Please be aware that:

› SUBOXONE sublingual film is indicated for the treatment of opioid
dependence.

› SUBOXONE sublingual tablets, including generic equivalents,
Zubsolv sublingual tablets, and Bunavall buccal film are indicated for
the maintenance treatment of opioid dependence after Initial Induction.

› SUBUTEX sublingual tablets and generic equivalents are indicated for the
treatment of opioid dependence.

› Patients physically dependent on heroin or other short-acting opioids
may initiate treatment (induct) with either SUBOXONE sublingual film
or with a buprenorphine-only sublingual product.

› SUBUTEX sublingual tablets and generic equivalent buprenorphine-only
tablets are preferred for induction for patients physically dependent on
methadone or long-acting opioids taken as per approved labeling.

› SUBOXONE sublingual film or tablets are preferred over buprenorphine-
only products for unsupervised administration.

› All of these products are used as part of a complete treatment plan,
including counseling and/or psychosocial support.

Indivior Inc.
10710 Midlothian Turnpike
Richmond, VA 23235
USA
+1 (804) 379-1090 T
+1 (804) 379-1215 F
indivior.com

Reference ID: 3822165
**Serious Risks of Buprenorphine-containing Products**

Please communicate the following key messages to patients about the risks of accidental overdose, misuse, and abuse while taking buprenorphine-containing products:

› Warn patients that it is extremely dangerous to self-administer non-prescribed benzodiazepines or other central nervous system (CNS) depressants (including alcohol) with these products. Caution patients prescribed benzodiazepines or other CNS depressants to use them only as directed by their prescriber.

› Instruct patients to keep buprenorphine-containing products in a secure place and out of the sight and reach of children. Accidental or deliberate ingestion by a child may cause respiratory depression that can result in death. If a child is exposed to one of these products, medical attention should be sought immediately.

› Advise patients that buprenorphine-containing products contain an opioid that can be a target for people who abuse prescription medications or street drugs. Caution patients to keep their products in a safe place, and to protect them from theft.

› Instruct patients never to give buprenorphine-containing products to anyone else, even if he or she has the same signs and symptoms. It may cause harm or death.

› Advise patients that selling or giving away buprenorphine-containing products is against the law.

**Pharmacist Action**

You are encouraged to read the enclosed educational brochure entitled *Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Pharmacists*. Each time you fill a prescription for buprenorphine-containing products, make sure to:

› Verify that the prescription you receive is from a prescriber who is in compliance with the provisions of DATA 2000

› Keep in mind that a limited supply of buprenorphine-containing products should be dispensed during the initiation of therapy. This is due to the need of prescribers to closely and frequently assess the patients’ needs, their symptoms, and potential risk of misuse, diversion, and abuse

› Provide the Medication Guide to patients each time the medicine is dispensed

› Remind patients who are picking up induction doses, to return as directed to the doctor’s office so that they can be supervised while taking the medication

› Provide appropriate patient counseling on the safe use of buprenorphine-containing products

› Be vigilant in detecting fraudulent prescriptions or simultaneous prescriptions for the same patient from multiple prescribers
Medication Guide

The SUBOXONE sublingual film, SUBOXONE sublingual tablets, and SUBUTEX sublingual tablets REMS include product specific Medication Guides on the safe and effective use of SUBOXONE sublingual film, SUBOXONE sublingual tablets, and SUBUTEX sublingual tablets. Provide a Medication Guide to your patients or their caregivers with each dispensing and encourage them to read it. Please also promote the importance of participating in a complete treatment program that may include counseling, behavioral therapy, and/or psychosocial support.

Reporting Adverse Events

To report SUSPECTED ADVERSE EVENTS contact:

- Indivior Inc. at 1-877-782-6966 or
- FDA MedWatch program by phone at 1-800-FDA-1088 or online at www.fda.gov/medwatch/report.htm

This letter is not a comprehensive description of the risks associated with the use of buprenorphine-containing products. Additional important safety information can be found in the Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Pharmacists educational brochure and Full Prescribing Information.


Sincerely,

<NAME>

<TITLE>

Indivior Inc.

Enclosures:

Pharmacist Brochure: Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Pharmacists